Targeting both SHMT1 and SHMT2 together was recently shown to be more effective in T-cell acute lymphoblastic leukemia (T-ALL) therapy [23], and the inhibitors working on both SHMT1 and 2 were sensitive on methotrexate-resistant cell lines as well [23]. This evidence concerns the gene SHMT1 and acute lymphoblastic leukemia.